Advertisement
U.S. markets closed
Advertisement

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
28.91-1.56 (-5.12%)
At close: 04:00PM EST
28.91 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close30.47
Open28.97
Bid28.87 x 4000
Ask28.87 x 4000
Day's Range28.30 - 29.40
52 Week Range28.30 - 54.93
Volume103,187,110
Avg. Volume30,620,631
Market Cap163.238B
Beta (5Y Monthly)0.58
PE Ratio (TTM)15.80
EPS (TTM)1.83
Earnings DateJan 29, 2024 - Feb 02, 2024
Forward Dividend & Yield1.64 (5.67%)
Ex-Dividend DateNov 09, 2023
1y Target Est40.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pfizer, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Motley Fool

    Is Pfizer Stock a Buy Now?

    Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?

  • Motley Fool

    Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes

    One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.

  • Motley Fool

    An Important History Lesson for Gene-Editing Investors

    Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.